| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRKL |
| Uniprot No | P46109 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-303aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSSARFDSSDRSAWYMGPVSRQEAQTRLQG QRHGMFLVRDSSTCPGDYVLSVSENSRVSHYIINSLPNRRFKIGDQEFDH LPALLEFYKIHYLDTTTLIEPAPRYPSPPMGSVSAPNLPTAEDNLEYVRT LYDFPGNDAEDLPFKKGEILVIIEKPEEQWWSARNKDGRVGMIPVPYVEK LVRSSPHGKHGNRNSNSYGIPEPAHAYAQPQTTTPLPAVSGSPGAAITPL PSTQNGPVFAKAIQKRVPCAYDKTALALEVGDIVKVTRMNINGQWEGEVN GRKGLFPFTHVKIFDPQNPDENE |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CRKL重组蛋白的3条参考文献概览(文献信息为模拟示例，具体内容需根据实际文献调整)：
1. **文献名称**：*Structural Insights into CRKL SH2 Domain Interactions*
**作者**：Matsuda M., et al.
**摘要**：本研究通过X射线晶体学解析了CRKL重组蛋白的SH2结构域三维结构，揭示了其特异性识别磷酸化酪氨酸残基的分子机制，并探讨了其在细胞信号转导中衔接上下游蛋白的功能基础。
2. **文献名称**：*CRKL Recombinant Protein Facilitates BCR-ABL-Driven Leukemogenesis*
**作者**：Senechal K., et al.
**摘要**：文章利用重组CRKL蛋白进行体外结合实验，证明其通过SH3结构域与BCR-ABL癌蛋白相互作用，进而激活RAS-MAPK通路，促进慢性粒细胞白血病(CML)的进展，为靶向治疗提供依据。
3. **文献名称**：*Expression and Functional Analysis of CRKL in Epithelial-Mesenchymal Transition*
**作者**：Wang Y., et al.
**摘要**：研究通过大肠杆菌系统表达重组CRKL蛋白，发现其过表达可增强TGF-β诱导的上皮间质转化(EMT)，并证实CRKL通过调控整合素信号通路影响肿瘤细胞迁移能力。
4. **文献名称**：*CRKL as an Adaptor in Immune Signaling Pathways*
**作者**：Smith J., et al.
**摘要**：该研究利用纯化的重组CRKL蛋白进行体外Pull-down实验，揭示了其与T细胞受体下游效应分子(如C3G)的动态结合，阐明CRKL在免疫突触形成及淋巴细胞活化中的关键作用。
注：以上文献信息为基于领域知识的模拟概括，实际引用时请以真实文献数据为准，建议通过PubMed或Web of Science以“CRKL recombinant protein”为关键词检索最新研究。
CRKL (CT10-regulated kinase-like) is a ubiquitously expressed adaptor protein belonging to the CRK family, which plays critical roles in intracellular signaling networks. It contains one SH2 domain and two SH3 domains that mediate protein-protein interactions by recognizing phosphorylated tyrosine residues and proline-rich motifs, respectively. CRKL serves as a molecular linker connecting cell surface receptors (e.g., growth factor receptors, integrins) to downstream effectors involved in cell proliferation, migration, and survival. It is notably implicated in cancer progression through its interaction with BCR-ABL1 in chronic myeloid leukemia and RAS-MAPK pathways in solid tumors.
Recombinant CRKL proteins are engineered using expression systems (e.g., E. coli, mammalian cells) to study its structure-function relationships and signaling mechanisms. These purified proteins enable in vitro analyses such as binding assays, kinase activity studies, and structural determinations (e.g., X-ray crystallography). Researchers utilize recombinant CRKL to investigate its role in diseases, including its oncogenic potential when dysregulated and its interaction with therapeutic targets. Additionally, they serve as antigens for antibody development or tools for screening small-molecule inhibitors. Recent studies also explore CRKL's involvement in immune regulation and infectious diseases, such as its hijacking by pathogens during infection. The production of functionally active recombinant CRKL remains essential for deciphering its complex signaling networks and developing targeted therapies.
×
